High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Cancer Statistics, 2007

2007 • 7,372 citations

Genetic Alterations during Colorectal-Tumor Development

1988 • 6,691 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 • 1,432 citations

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

2007 • 1,111 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 • 1,081 citations

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

2001 • 858 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

2007 • 817 citations

Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study

1998 • 739 citations

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

2007 • 737 citations

Monoclonal antibodies to target epidermal growth factor receptor–positive tumors

2002 • 453 citations

Sample size tables for exact single‐stage phase II designs

2001 • 367 citations

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

2007 • 318 citations

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

2007 • 265 citations

Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

2004 • 259 citations

Different Genetic Features Associated with Colon and Rectal Carcinogenesis

2004 • 220 citations

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

2006 • 177 citations

K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients.

1997 • 79 citations

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options

2007 • 47 citations